RxDoctor Payments Data

James McCarthy, MD

Neurology · Hyannis, MANPI 1245337963

Payments from drug & device makers

$1,696in general payments, 2019–2025

Across 86 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$718
  • Sanofi$140
  • Sunovion Pharmaceuticals Inc.$114
  • Amneal Pharmaceuticals LLC$113
  • Lilly USA, LLC$103
  • Novartis$100
  • plus $408 from 12 others

What the payments were for

  • Food & beverage$1,68499%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,696 in reported general payments places this provider in the 55th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$118,798
Medicare patients
662
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin19$198,252
BetaseronInterferon Beta-1b13$124,593
TecfideraDimethyl Fumarate11$99,361
Nurtec OdtRimegepant Sulfate41$82,350
Tetrabenazine11$67,887
Aimovig AutoinjectorErenumab-Aooe33$34,945
UbrelvyUbrogepant27$33,161
TopamaxTopiramate16$28,978
VimpatLacosamide23$26,362
QuliptaAtogepant14$15,588
Levetiracetam364$14,522
DilantinPhenytoin Sodium Extended33$11,860
KeppraLevetiracetam12$9,544
RytaryCarbidopa/Levodopa15$7,674
Carbamazepine ErCarbamazepine63$6,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$32$99,36111 claims
PfizerNurtec Odt, Dilantin, Dilantin$20$96,74187 claims
AbbVieUbrelvy, Qulipta$718$48,74941 claims
Amneal Pharmaceuticals LLCRytary$113$7,67415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 761 neurology providers in Massachusetts.

Other neurology in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →